Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
 |
2025 –2032 |
 |
USD 345.10 Million |
 |
USD 613.11 Million |
 |
% |
|
|
Global Sarilumab Market Segmentation, By Dosage (Injection and Solution), Route of administration (Subcutaneous and Parenteral), Type (Antirheumatic, Interleukin-6 Receptor Antagonist, and Monoclonal Antibody), Application (Rheumatoid Arthritis, Community-acquired Pneumonia, and Others), Demographic (Adult and Geriatric), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032
Sarilumab, a humanized monoclonal antibody, has gained significant attention in the biopharmaceutical market for its role in treating moderate to severe rheumatoid arthritis (RA). The sarilumab market has seen significant advancements, particularly in the expanding use of the drug for COVID-19 treatment, where it has shown effectiveness in reducing inflammation in severe cases. Ongoing clinical trials are investigating its potential in other autoimmune diseases such as systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis, and even in combination therapies with other RA treatments. Despite its promise, the sarilumab market faces challenges, including competition from other RA biologics, concerns over side effects, and the high cost of treatment, which may limit accessibility in low-resource regions. However, with increasing research and new indications, the sarilumab market is expected to grow as more treatment options emerge.
The global sarilumab market size was valued at USD 345.10 million in 2024 and is projected to reach USD 613.11 million by 2032, with a CAGR of 7.45% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Sarilumab Market Trends
“Increasing Adoption of Biologic Therapies”
A key trend in the sarilumab market is the increasing adoption of biologic therapies for the treatment of autoimmune diseases. Sarilumab, a monoclonal antibody and interleukin-6 (IL-6) receptor antagonist, has gained significant traction in managing conditions such as rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA). For instance, in 2021, Sanofi and Regeneron expanded the approval of sarilumab to include the treatment of active pJIA in children, further driving its market penetration. This trend is driven by the growing demand for more effective and targeted therapies, particularly in patients who have not responded to traditional disease-modifying antirheumatic drugs (DMARDs). Additionally, increasing awareness and improving healthcare infrastructure, especially in emerging markets, are contributing to the widespread use of biologics such as sarilumab. As the number of patients diagnosed with autoimmune diseases continues to rise globally, the sarilumab market is poised for continued growth and expansion.
Report Scope and Sarilumab Market Segmentation
|
Attributes
|
Sarilumab Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Regeneron Pharmaceuticals Inc (U.S.) and Sanofi (France)
|
|
Market Opportunities
|
Growing Supportive Regulatory Approvals
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Sarilumab Market Definition
Sarilumab is a monoclonal antibody that functions as an interleukin-6 (IL-6) receptor antagonist, designed to reduce inflammation by blocking the activity of IL-6, a cytokine involved in the immune response. It is primarily used to treat autoimmune disorders such as rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) in patients who have not responded adequately to traditional treatments. By targeting the IL-6 pathway, sarilumab helps manage symptoms such as joint pain, swelling, and stiffness, while also slowing disease progression.
Sarilumab Market Dynamics
Drivers
The rising prevalence of autoimmune diseases is a significant driver of the sarilumab market, as conditions such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) continue to increase globally. According to the Centers for Disease Control and Prevention (CDC), approximately 1.3 million adults in the U.S. are affected by RA, a chronic inflammatory condition that can lead to joint damage and disability if left untreated. Moreover, the National Institute of Health (NIH) estimates that JIA affects nearly 300,000 children in the U.S., making it the most common pediatric autoimmune disease. The growing need for advanced therapies to manage these conditions, particularly for patients who do not respond adequately to traditional disease-modifying antirheumatic drugs (DMARDs), has boosted the adoption of sarilumab, an IL-6 receptor antagonist. Its targeted mechanism of action and efficacy in reducing inflammation and halting disease progression make it an essential treatment option, driving its demand in the global market.
The increasing geriatric population is a key driver of the sarilumab market, as older adults are more susceptible to developing autoimmune disorders such as rheumatoid arthritis (RA). According to the United Nations, the global population aged 65 and older is projected to reach 1.5 billion by 2050, nearly doubling from 727 million in 2020. In the U.S. alone, the CDC reports that nearly 50% of adults aged 65 and older live with arthritis, significantly impacting their quality of life and mobility. This demographic shift has intensified the demand for effective, targeted therapies such as sarilumab, an IL-6 receptor antagonist that helps manage inflammation and joint damage in autoimmune conditions. As the elderly population grows and their healthcare needs become more complex, the market for advanced treatments such as sarilumab is expected to expand, making it a critical component of autoimmune disease management globally.
Opportunities
Advancements in monoclonal antibody technology have significantly enhanced the effectiveness and safety profile of treatments such as sarilumab, creating a notable market opportunity. Innovations in antibody engineering have improved the drug’s ability to specifically target the interleukin-6 (IL-6) receptor, a key contributor to inflammation in autoimmune diseases such as rheumatoid arthritis (RA). For instance, sarilumab’s design allows for high receptor binding affinity, ensuring sustained therapeutic effects with less frequent dosing. This increases patient compliance and minimizes adverse reactions, such as injection site irritation, compared to earlier biologics. Additionally, advancements have enabled the production of biosimilars, making such treatments more affordable and accessible in emerging markets. These technological strides are driving the growing preference for sarilumab in managing chronic inflammatory conditions, presenting a robust growth opportunity in the biologic therapies market.
Supportive regulatory approvals are creating significant market opportunities for sarilumab by expanding its applications and accessibility. For instance, the U.S. Food and Drug Administration (FDA) recently approved sarilumab for treating polyarticular juvenile idiopathic arthritis (pJIA) in children weighing at least 63 kg. Such regulatory support broadens the drug's therapeutic reach and fosters its adoption in pediatric care settings, complementing its established use in managing rheumatoid arthritis. Furthermore, approvals for innovative delivery methods, such as prefilled syringes or self-administration devices, enhance patient convenience and compliance. These advancements, backed by regulatory endorsements, are driving sarilumab's penetration into untapped patient populations, thereby strengthening its position in the autoimmune therapeutics market.
Restraints/Challenges
The high cost of treatment with sarilumab is a significant market challenge, particularly in regions with limited healthcare resources or for patients without comprehensive insurance coverage. As a biologic therapy, sarilumab involves complex and costly manufacturing processes, which are reflected in its market price. For instance, patients with moderate to severe rheumatoid arthritis who require long-term sarilumab therapy may face substantial financial strain, especially in low- and middle-income countries where access to affordable biologics is limited. This high cost creates barriers for individual patients and places a heavy burden on healthcare systems, particularly those with constrained budgets. For instance, public healthcare programs in developing nations may prioritize cheaper, more established treatments, reducing sarilumab's adoption despite its clinical efficacy. This affordability challenge limits the reach of sarilumab to a broader patient population, highlighting the need for cost-reduction strategies, such as the development of biosimilars or government-subsidized programs, to enhance its accessibility and competitive position in the market.
Side effects and safety concerns present a significant challenge for the sarilumab market, as the drug is associated with adverse events such as neutropenia (a reduction in white blood cell count), elevated liver enzymes, and an increased risk of infections. These issues are particularly concerning for patients with pre-existing conditions, such as chronic liver disease or compromised immune systems, where the risk of complications is heightened. For instance, a rheumatoid arthritis patient with a history of recurrent infections may be less likely to receive sarilumab due to the potential for exacerbating their condition. Additionally, monitoring for such sarilumab side effects requires regular clinical laboratory tests and physician oversight, which can increase the overall cost and complexity of treatment. These safety risks may deter both physicians and patients from opting for sarilumab, despite its proven efficacy, especially when safer alternatives are available. Consequently, these concerns act as a market challenge, emphasizing the need for improved safety profiles, risk mitigation strategies, and targeted patient education to build confidence in its use.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The market is segmented on the basis of dosage, route of administration, type, application, demographic, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Dosage
Route of Administration
Type
Application
Demographic
End-Users
Distribution Channel
The market is analysed and market size insights and trends are provided by country, dosage, route of administration, type, application, demographic, end-users, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America holds a dominant position in the Sarilumab market, driven by the presence of leading pharmaceutical companies and key market players. The rising prevalence of fungal infections, coupled with an increasing reliance on antifungal medications, is fueling market growth in this region. Additionally, North America's well-established healthcare infrastructure and advanced treatment options further contribute to the demand for Sarilumab. The strong market presence of established brands and healthcare institutions in the U.S. and Canada supports continued growth in the Sarilumab market.
Asia-Pacific is anticipated to experience significant growth during the forecast period, driven by the increasing focus of pharmaceutical companies on advancing therapies for various diseases, including fungal infections. Government initiatives and support for healthcare infrastructure and innovation are also contributing to the region's market expansion. Furthermore, the rising investment in research and development activities across countries such as China, India, and Japan is accelerating the discovery of new treatments. These factors combined are expected to foster a thriving pharmaceutical market, boosting the demand for Sarilumab and similar therapies in Asia-Pacific.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Sarilumab Market Leaders Operating in the Market Are:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
The market is segmented based on Segmentation, By Dosage (Injection and Solution), Route of administration (Subcutaneous and Parenteral), Type (Antirheumatic, Interleukin-6 Receptor Antagonist, and Monoclonal Antibody), Application (Rheumatoid Arthritis, Community-acquired Pneumonia, and Others), Demographic (Adult and Geriatric), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032 .
The Global Sarilumab Market size was valued at USD 345.10 USD Million in 2024.
The Global Sarilumab Market is projected to grow at a CAGR of 7.45% during the forecast period of 2025 to 2032.
The major players operating in the market include Regeneron Pharmaceuticals Inc and Sanofi .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
